RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response.
about
MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancerMultidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseasesThe effect of ABCB1 polymorphisms on the outcome of breast cancer treatmentMVP and vaults: a role in the radiation responseDisrupting P-glycoprotein function in clinical settings: what can we learn from the fundamental aspects of this transporter?Circulating MiR-125b as a marker predicting chemoresistance in breast cancerAssociation of drug transporter expression with mortality and progression-free survival in stage IV head and neck squamous cell carcinomaNeoadjuvant chemotherapy induces expression levels of breast cancer resistance protein that predict disease-free survival in breast cancerDifferential expression of metallothionein 1 and 2 isoforms in breast cancer lines with different invasive potential: identification of a novel nonsilent metallothionein-1H mutant variant.Whole genome expression and biochemical correlates of extreme constitutional types defined in AyurvedaDifferential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2).Evaluating the response of neoadjuvant chemotherapy for treatment of breast cancer: are tumor biomarkers and dynamic contrast enhanced MR images useful predictive tools?Transferrin-targeted polymeric micelles co-loaded with curcumin and paclitaxel: efficient killing of paclitaxel-resistant cancer cells.Modulation of the major histocompatibility complex by neural stem cell-derived neurotrophic factors used for regenerative therapy in a rat model of strokeUpdate information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters.Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepiloneThe mammary cellular hierarchy and breast cancer.Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma.Ixabepilone (ixempra), a therapeutic option for locally advanced or metastatic breast cancer.Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer.Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.The challenge of exploiting ABCG2 in the clinic.Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo.Therapeutic melting pot of never in mitosis gene a related kinase 2 (Nek2): a perspective on Nek2 as an oncology target and recent advancements in Nek2 small molecule inhibitionMulti-drug resistance 1 genetic polymorphism and prediction of chemotherapy response in Hodgkin's LymphomaABCG2 is associated with HER-2 expression, lymph node metastasis and clinical stage in breast invasive ductal carcinoma.High glucose promotes gastric cancer chemoresistance in vivo and in vitroReversing multidrug resistance in breast cancer cells by silencing ABC transporter genes with nanoparticle-facilitated delivery of target siRNAs.Chemotherapy curable malignancies and cancer stem cells: a biological review and hypothesisRole of the breast cancer resistance protein (ABCG2) in drug transport.Breast cancer resistance protein (BCRP)-containing circulating microvesicles contribute to chemoresistance in breast cancerPrognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patientsSingle-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells.Reversal of multidrug resistance by cisplatin-loaded magnetic Fe3O4 nanoparticles in A549/DDP lung cancer cells in vitro and in vivoTargeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies.Membrane expression of MRP-1, but not MRP-1 splicing or Pgp expression, predicts survival in patients with ESFT.Anthracycline Nano-Delivery Systems to Overcome Multiple Drug Resistance: A Comprehensive Review.MRP1-CD28 bi-specific oligonucleotide aptamers: target costimulation to drug-resistant melanoma cancer stem cellsInhibition of gamma-secretase induces G2/M arrest and triggers apoptosis in breast cancer cells.
P2860
Q21195215-56FE2756-2FBD-4356-A5C1-4E0F3C4342D9Q24601963-0BEE0923-90B5-4E89-A5F0-90363FEBA61FQ26749954-52E5DAFA-E9C0-4D8C-9FBE-82462642445CQ26865123-44D555CE-3FC5-4D2C-A739-48AD3AD8902FQ28069761-91FCAA49-C21F-42DB-8DF7-DC3373B0314BQ28482362-F32D88E1-DA32-4E22-87FC-D0EE41A670D2Q28543497-1DD67A77-5AFD-4AB0-A0D3-8846C5F8E08BQ28706276-74D71DD7-9AF8-4AFF-8D33-6EC82DD4A2C2Q30336222-BD2A7A19-6B3E-4F11-964D-B69F7417E4C8Q30483933-2ACDDC03-E68E-4ED1-931F-E55E2FA414E4Q33523365-D3746D14-3D50-4880-9F0A-594AB43AE5AEQ33814616-50C30B42-8EE0-4B35-80BA-2E1945369F79Q34047136-EDDAE7EC-B09D-49D9-A1ED-71ED048C1CC4Q34114142-A06E5031-D950-49E8-AE1D-7C1DBFBE5A28Q34204238-41EED4D2-9187-40B2-8CB4-047DAC02714AQ34274930-C3E8D184-5C3A-44F1-BACD-54E7357B7CE4Q34396558-C98F5ED6-AE31-46F1-B36F-84FEE22498C8Q34478227-58605399-9FCE-4C83-A8AE-689DD3AD8D00Q34611801-3F4C53E3-C14E-4435-8B1F-017902C0B604Q34661616-551598BD-A242-4A83-B9BA-8B3564958EB5Q34871636-965E94C5-9F71-4CC8-9705-C82A3B1C38C1Q34968909-5AB800F7-A7EA-4485-B80A-3DAA949E767BQ35067898-B816FAFA-69DA-401E-9F39-E27098D1C050Q35092019-74B30AA2-9C1C-430C-BF50-5CA7CCB99F91Q35158345-7FCCCD7A-9A74-4740-92CD-13FAC92B32BBQ35318963-87723B5A-A492-4FA9-803F-586A86834681Q35628554-A14BA3A8-CC39-454E-991D-529F156E5E4FQ36027132-59B27B66-B4D8-4230-B731-E85518B173E3Q36200232-370424B2-5EB8-4DF0-9512-3C54665DD13FQ36250753-82B00447-13F4-4807-9D28-ED729F5941AEQ36334251-E91E852A-7CD4-44AA-ACF8-CEC033AC3E14Q36613823-AC40911A-21E3-4FA3-8DE6-9A97D8D57552Q36662847-F5320858-39A9-4A93-96DE-16F5BC5D973BQ36719279-5434E396-1B6B-45E4-A619-0C1CFA41EE3BQ36851857-1290C801-472F-4527-9CA3-6FC12E65E206Q36923104-DEA83AAA-425C-442B-AD66-7F2A3B4FF6CFQ37003304-B96D7DC4-B74E-4639-BD3C-0D32AA0748FCQ37031597-7FDA1C71-7239-4AA0-A338-0312167D17D0Q37268962-CD004C92-CA52-49A6-AC60-45461E57F297Q37271116-1B0CECE8-8080-47E8-A23D-98B81AB310BA
P2860
RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response.
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
RNA expression of breast cance ...... ith chemotherapeutic response.
@ast
RNA expression of breast cance ...... ith chemotherapeutic response.
@en
type
label
RNA expression of breast cance ...... ith chemotherapeutic response.
@ast
RNA expression of breast cance ...... ith chemotherapeutic response.
@en
prefLabel
RNA expression of breast cance ...... ith chemotherapeutic response.
@ast
RNA expression of breast cance ...... ith chemotherapeutic response.
@en
P2093
P1476
RNA expression of breast cance ...... with chemotherapeutic response
@en
P2093
Erik A C Wiemer
Gerrit Stoter
Herman Burger
Jan G M Klijn
John A Foekens
Kees Nooter
Marion E Meijer-van Gelder
Maxime P Look
P304
P407
P577
2003-02-01T00:00:00Z